leisure time -WSS

leisure time

author：entertainment 2025-09-30 15:16:55 - browse：313

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： For AI in health care standards, federal regulators join with industry group

WSS

Editas, Vertex strike deal on CRISPR

Lack of health data on LGBTQ+ people has serious consequences

In Spain, a hospital brews its own CAR

How to keep neuroscience’s past racism from being its future

Florida health officials providing scant details on measles cases

Biden's 'march

explore

leisure time

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Medicare drug price negotiation continues, as pharma counteroffers

Activists slam private health insurers over coverage restrictions

$1 billion proposal to grow Boston, Massachusetts biotech

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

HCA sued by state AG for quality issues at Mission Health

Bright Health sells Medicare Advantage business to Molina

Carvykti CAR

Activists slam private health insurers over coverage restrictions

Virtual care provider acquires bankrupt Pear's prescription apps

focus

Bristol Myers buys into radiopharmaceuticals with RayzeBio

HCA sued by state AG for quality issues at Mission Health

First over

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Longer MASH drug regimen improved liver, Akero study finds

Change Healthcare: What is it, why does its cyberattack matter?

hotspot

entertainment

explore

explore